��ҳ| �鶹��ýӳ��

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.

This year has been a major year in the field of Alzheimer disease (AD), with several promising therapies moving forward and the first FDA approval in almost 2 decades.

It’s called the Chambers-Grundy Center for Transformative Neuroscience at UNLV, and the adjective in the name says it all.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts.

Pharmacological studies have attempted and failed for past decades to generate medicines that might halt the course of the illness. Now, experts claim to have reached a tipping point in Alzheimer's development.

The cause of Alzheimer’s was supposedly simple.

Alzheimer’s treatments seemed unlikely just a few months ago.